Cargando…
Nonclinical development of novel biologics, biosimilars, vaccines and specialty biologics /
Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics is a complete reference devoted to the nonclinical safety assessment of novel biopharmaceuticals, biosimilars, vaccines, cell and gene therapies and blood products. This book compares and contrasts these types...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam :
Academic Press,
2013.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Ia 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn853564688 | ||
| 003 | OCoLC | ||
| 005 | 20231117044909.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 130723s2013 ne a o 000 0 eng d | ||
| 040 | |a N$T |b eng |e pn |c N$T |d UIU |d CUX |d TEFOD |d TPH |d UPM |d OCLCF |d OCLCQ |d E7B |d GGVRL |d COO |d TEFOD |d OCLCQ |d UAB |d OCLCO |d CASUM |d MERER |d OCLCQ |d OCLCO |d OCLCQ |d U3W |d D6H |d OCLCO |d OCLCQ |d YDX |d AU@ |d UWO |d S2H |d OCLCO |d OCLCA |d OCLCO |d OCL |d OCLCQ |d OCLCO | ||
| 019 | |a 860713555 |a 1058340925 |a 1067204988 | ||
| 020 | |a 9780123948236 |q (electronic bk.) | ||
| 020 | |a 0123948231 |q (electronic bk.) | ||
| 020 | |z 9780123948106 | ||
| 020 | |z 012394810X | ||
| 035 | |a (OCoLC)853564688 |z (OCoLC)860713555 |z (OCoLC)1058340925 |z (OCoLC)1067204988 | ||
| 050 | 4 | |a RM301.4 | |
| 060 | 4 | |a QW 800 | |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 082 | 0 | 4 | |a 615.7 |2 23 |
| 245 | 0 | 0 | |a Nonclinical development of novel biologics, biosimilars, vaccines and specialty biologics / |c edited by Lisa Plitnick, Danuta Herzyk. |
| 264 | 1 | |a Amsterdam : |b Academic Press, |c 2013. | |
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |a Front Cover; Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics; Copyright; Dedication; Contents; Preface; Contributors; Acknowledgments; Section I Development of Biopharmaceuticals Defined as Novel Biologics; Chapter 1 -- Overview of Biopharmaceuticals and Comparison with Small-molecule Drug Development; INTRODUCTION; HISTORY AND EVOLUTION OF BIOPHARMACEUTICALS; DEVELOPMENT OF DIVERSE BIOPHARMACEUTICAL MODALITIES; COMPARISON OF SMALL-MOLECULE DRUGS TO BIOPHARMACEUTICALS; SUMMARY; References. | |
| 505 | 8 | |a Chapter 2 -- Regulatory Guidelines and their Application in the Nonclinical Evaluation of Biological MedicinesINTRODUCTION; SPECIES SELECTION; STUDY DESIGN CONSIDERATIONS FOR REPEAT-DOSE STUDIES; IMMUNOGENICITY; REPRODUCTIVE AND DEVELOPMENTAL TOXICITY; GENOTOXICITY AND CARCINOGENICITY; SPECIAL CONSIDERATIONS FOR ANTICANCER DRUGS; FIRST-IN-HUMAN (FIH) CLINICAL TRIAL; SUMMARY; References; Chapter 3 -- Early De-risking Strategy for Novel Biotherapeutics; INTRODUCTION; ESTABLISHING A SAFETY PROFILE FOR BIOTHERAPEUTICS; GENERAL SAFETY CONSIDERATIONS RELATED TO BIOTHERAPEUTICS. | |
| 505 | 8 | |a PROGRESS IN EVALUATION OF IMMUNOTOXICITYCAN WE BETTER ADDRESS POTENTIAL OFF-TARGET TOXICITY?; SUMMARY; References; Chapter 4 -- Novel Biopharmaceuticals: Pharmacokinetics, Pharmacodynamics, and Bioanalytics; INTRODUCTION; ABSORPTION, DISTRIBUTION AND ELIMINATION OF BIOPHARMACEUTICALS; DISPOSITION OF MODIFIED MOLECULES; "METABOLISM" AND BIODISTRIBUTION FOR BIOPHARMACEUTICALS; IMMUNOGENICITY AND IMPACTS ON PK AND BIODISTRIBUTION; PHARMACOKINETICS AND PHARMACODYNAMICS; PRECLINICAL TO CLINICAL TRANSLATION; BIOANALYTICS; DRUG ASSAYS; BIOMARKERS: TARGET ENGAGEMENT ASSAYS. | |
| 505 | 8 | |a IMMUNOGENICITY ASSESSMENT: ADA ASSAYSSUMMARY; References; Section II Development of Biosimilars; Chapter 5 -- Overview of Biosimilar Therapeutics; INTRODUCTION; THE CONCEPT OF BIOSIMILARS; GENERAL CONSIDERATIONS FOR DEVELOPMENT OF BIOSIMILARS; BIOSIMILAR CANDIDATES BASED ON MODALITY AND THERAPEUTIC CLASS; SUMMARY; References; Chapter 6 -- Regulatory Standards for the Approval of Biosimilar Products: A Global Review; INTRODUCTION; EUROPEAN UNION-PIONEER FOR THE FIRST REGULATORY PATHWAY FOR BIOSIMILAR PRODUCTS; THE WORLD HEALTH ORGANIZATION GUIDANCE ON BIOSIMILARS. | |
| 505 | 8 | |a REGULATORY PATHWAY FOR BIOSIMILAR PRODUCTS IN THE UNITED STATESBIOSIMILAR PATHWAYS IN OTHER REGIONS; SUMMARY; References; Chapter 7 -- Early Characterization of Biosimilar Therapeutics; INTRODUCTION; RECOMBINANT INSULINS; RECOMBINANT HUMAN GROWTH HORMONE; RECOMBINANT ERYTHROPOIETINS; RECOMBINANT GRANULOCYTE COLONY-STIMULATING FACTOR; RECOMBINANT INTERFERONS; LOW MOLECULAR WEIGHT HEPARINS; MONOCLONAL ANTIBODIES; OTHER CLASSES; SUMMARY; References; Section III Vaccines; Chapter 8 -- Introduction to Vaccines and Adjuvants; INTRODUCTION; THE HISTORY OF VACCINES. | |
| 520 | |a Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics is a complete reference devoted to the nonclinical safety assessment of novel biopharmaceuticals, biosimilars, vaccines, cell and gene therapies and blood products. This book compares and contrasts these types of biologics with one another and with small molecule drugs, while incorporating the most current and essential international regulatory documents. Each section discusses a different type of biologic, as well as early characterization strategies, principles of study design, preclinical pha. | ||
| 504 | |a Includes bibliographical references and index. | ||
| 650 | 0 | |a Biologicals. | |
| 650 | 0 | |a Biological products. | |
| 650 | 0 | |a Biopharmaceutics. | |
| 650 | 0 | |a Vaccines. | |
| 650 | 1 | 2 | |a Biological Factors |0 (DNLM)D001685 |
| 650 | 2 | 2 | |a Vaccines |0 (DNLM)D014612 |
| 650 | 2 | |a Biopharmaceutics |0 (DNLM)D001702 | |
| 650 | 2 | |a Biological Products |0 (DNLM)D001688 | |
| 650 | 6 | |a Produits biologiques. |0 (CaQQLa)201-0003884 | |
| 650 | 6 | |a Biopharmacie. |0 (CaQQLa)201-0050334 | |
| 650 | 6 | |a Vaccins. |0 (CaQQLa)201-0018490 | |
| 650 | 6 | |a M�edicaments biologiques. |0 (CaQQLa)000343252 | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a Vaccines |2 fast |0 (OCoLC)fst01163573 | |
| 650 | 7 | |a Biological products |2 fast |0 (OCoLC)fst00832292 | |
| 650 | 7 | |a Biologicals |2 fast |0 (OCoLC)fst00832374 | |
| 650 | 7 | |a Biopharmaceutics |2 fast |0 (OCoLC)fst00832650 | |
| 655 | 4 | |a Internet Resources. | |
| 700 | 1 | |a Plitnick, Lisa M., |e editor. | |
| 700 | 1 | |a Herzyk, Danuta J., |e editor. | |
| 776 | 0 | 8 | |i Print version: |t Nonclinical development of novel biologics, biosimilars, vaccines and specialty biologics |z 9780123948106 |w (OCoLC)852806062 |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780123948106 |z Texto completo |